Scan to Download ios&Android APP

Trade Precigen, Inc. - PGEN CFD

2.11
5.8%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 2.24
Open* 2.21
Day's Range* 2.11 - 2.11
1-Year Change* 4.74%
Volume N/A
Average Vol. (3m) 33.3273
52 wk Range N/A
Market Cap 474.582
P/E Ratio N/A
Shares Outstanding 208150000
Revenue 54.206
EPS -0.52469
Dividend (Yield %) N/A
Beta 2.34346
Next Earnings Date Nov 7, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 18, 2022 2.24 0.00 0.00% 2.24 2.27 2.17
Aug 17, 2022 2.25 -0.11 -4.66% 2.36 2.41 2.25
Aug 16, 2022 2.39 -0.16 -6.27% 2.55 2.56 2.34
Aug 15, 2022 2.59 0.28 12.12% 2.31 2.62 2.30
Aug 12, 2022 2.35 0.07 3.07% 2.28 2.41 2.28
Aug 11, 2022 2.30 -0.10 -4.17% 2.40 2.43 2.24
Aug 10, 2022 2.39 0.07 3.02% 2.32 2.43 2.17
Aug 9, 2022 2.30 0.24 11.65% 2.06 2.37 2.06
Aug 8, 2022 2.04 -0.01 -0.49% 2.05 2.09 1.97
Aug 5, 2022 2.05 0.01 0.49% 2.04 2.07 1.94
Aug 4, 2022 2.09 0.31 17.42% 1.78 2.14 1.78
Aug 3, 2022 1.76 0.08 4.76% 1.68 1.81 1.67
Aug 2, 2022 1.66 0.17 11.41% 1.49 1.66 1.48
Aug 1, 2022 1.52 0.02 1.33% 1.50 1.58 1.48
Jul 29, 2022 1.54 -0.03 -1.91% 1.57 1.58 1.50
Jul 28, 2022 1.58 -0.01 -0.63% 1.59 1.64 1.55
Jul 27, 2022 1.61 -0.16 -9.04% 1.77 1.78 1.61
Jul 26, 2022 1.77 0.02 1.14% 1.75 1.84 1.70
Jul 25, 2022 1.80 0.00 0.00% 1.80 1.88 1.76
Jul 22, 2022 1.80 -0.09 -4.76% 1.89 1.94 1.77

Precigen, Inc. Events

Time (UTC) Country Event
Monday, November 7, 2022
13:30
  US
Q3 2022 Precigen Inc Earnings Release
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 190.926 219.463 151.178 90.722 103.178 103.873
Revenue 190.926 219.463 151.178 90.722 103.178 103.873
Cost of Revenue, Total 61.639 61.692 62.676 61.401 55.513 58.385
Gross Profit 129.287 157.771 88.502 29.321 47.665 45.488
Total Operating Expense 316.092 315.373 520.845 257.511 189.781 183.191
Selling/General/Admin. Expenses, Total 142.318 130.682 125.162 98.634 91.704 74.122
Research & Development 112.135 109.176 333.007 66.666 41.644 50.141
Operating Income -125.166 -95.91 -369.667 -166.789 -86.603 -79.318
Interest Income (Expense), Net Non-Operating 9.329 6.411 1.558 -16.211 -17.087 -17.277
Other, Net -57.194 11.132 -27.803 11.736 -0.165 -0.33
Net Income Before Taxes -173.031 -78.367 -395.912 -171.264 -103.855 -96.925
Net Income After Taxes -169.154 6.87 -380.487 -170.334 -103.773 -96.765
Minority Interest 3.662 9.802 5.37 1.592 0 0
Equity In Affiliates -21.12
Net Income Before Extra. Items -186.612 16.672 -375.117 -168.742 -103.773 -96.765
Net Income -186.612 -117.018 -509.336 -322.324 -170.521 -92.166
Income Available to Common Excl. Extra. Items -186.612 16.672 -375.117 -168.742 -103.773 -96.765
Income Available to Common Incl. Extra. Items -186.612 -117.018 -509.336 -322.324 -170.521 -92.166
Diluted Net Income -186.612 -117.018 -509.336 -322.324 -170.521 -92.166
Diluted Weighted Average Shares 117.984 119.999 129.522 154.139 167.066 197.76
Diluted EPS Excluding Extraordinary Items -1.58167 0.13893 -2.89617 -1.09474 -0.62115 -0.48931
Diluted Normalized EPS -1.58167 0.21381 -2.89617 -0.96482 -0.61757 -0.48752
Unusual Expense (Income) 13.823 0 30.81 0.92 0.543
Total Extraordinary Items -133.69 -134.219 -153.582 -66.748 4.599
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 24.511 33.58 21.561 24.221 32.021
Revenue 24.511 33.58 21.561 24.221 32.021
Cost of Revenue, Total 12.976 15.033 15.45 14.926 17.099
Gross Profit 11.535 18.547 6.111 9.295 14.922
Total Operating Expense 42.199 49.254 47.03 44.708 49.917
Selling/General/Admin. Expenses, Total 18.702 19.997 18.66 16.763 19.576
Research & Development 10.521 13.681 12.92 13.019 12.76
Operating Income -17.688 -15.674 -25.469 -20.487 -17.896
Interest Income (Expense), Net Non-Operating -4.15 -4.257 -4.296 -4.574 -1.636
Other, Net -0.058 -0.192 -0.12 0.04 0.223
Net Income Before Taxes -21.896 -20.123 -29.885 -25.021 -19.309
Net Income After Taxes -21.844 -20.063 -29.824 -25.034 -19.251
Net Income Before Extra. Items -21.844 -20.063 -29.824 -25.034 -19.251
Total Extraordinary Items 4.526 0.013 0.06 0 0
Net Income -17.318 -20.05 -29.764 -25.034 -19.251
Income Available to Common Excl. Extra. Items -21.844 -20.063 -29.824 -25.034 -19.251
Income Available to Common Incl. Extra. Items -17.318 -20.05 -29.764 -25.034 -19.251
Diluted Net Income -17.318 -20.05 -29.764 -25.034 -19.251
Diluted Weighted Average Shares 193.5 199.022 199.18 199.276 199.629
Diluted EPS Excluding Extraordinary Items -0.11289 -0.10081 -0.14973 -0.12562 -0.09643
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.11289 -0.09903 -0.14973 -0.12562 -0.09486
Unusual Expense (Income) 0.543 0 0 0.482
Minority Interest 0
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 315.181 154.047 285.483 234.643 148.948 156.628
Cash and Short Term Investments 237.209 79.669 216.874 75.053 100.117 115.16
Cash & Equivalents 62.607 68.111 96.876 65.793 51.792 42.92
Short Term Investments 174.602 11.558 119.998 9.26 48.325 72.24
Total Receivables, Net 42.485 39.841 26.565 26.228 20.427 21.471
Accounts Receivable - Trade, Net 38.43 37.688 25.308 21.25 16.506 20.905
Total Inventory 21.139 20.493 20.575 16.097 11.359 13.261
Prepaid Expenses 7.361 7.057 5.327 6.444 7.192 6.736
Other Current Assets, Total 6.987 6.987 16.142 110.821 9.853 0
Total Assets 949.068 846.851 716.177 455.763 314.587 359.856
Property/Plant/Equipment, Total - Net 64.672 112.674 86.896 86.197 44.277 45.215
Property/Plant/Equipment, Total - Gross 98.722 158.32 135.946 135.329 79.229 84.437
Accumulated Depreciation, Total -34.05 -45.646 -49.05 -49.132 -34.952 -39.222
Goodwill, Net 157.175 153.289 93.627 63.754 54.363 54.148
Intangibles, Net 225.615 232.877 88.962 68.346 65.396 54.115
Long Term Investments 182.715 189.91 2.779 1.461 0 48.562
Other Long Term Assets, Total 3.71 4.054 158.43 1.362 1.603 1.188
Total Current Liabilities 94.605 80.173 61.562 122.912 42.127 34.645
Accounts Payable 8.478 8.701 11.973 5.917 4.598 5.405
Accrued Expenses 22.316 27.554 28.96 30.322 20.303 24.369
Notes Payable/Short Term Debt 0.82 0.233 0.466 1.922 0 0
Current Port. of LT Debt/Capital Leases 0.386 0.502 0.479 31.67 0.36 0.402
Other Current Liabilities, Total 62.605 43.183 19.684 53.081 16.866 4.469
Total Liabilities 388.831 313.22 353.322 384.052 247.413 252.508
Total Long Term Debt 7.562 7.535 211.216 186.321 171.522 182.749
Long Term Debt 7.562 7.535 211.216 186.321 171.522 182.749
Deferred Income Tax 17.007 15.62 3.856 2.834 2.897 2.539
Minority Interest 9.011 12.914 15.867 0
Other Liabilities, Total 260.646 196.978 60.821 71.985 30.867 32.575
Total Equity 560.237 533.631 362.855 71.711 67.174 107.348
Common Stock 0 0 0 0 0 0
Additional Paid-In Capital 1325.78 1397.01 1722.01 1752.05 1886.57 2022.7
Retained Earnings (Accumulated Deficit) -729.341 -847.82 -1330.55 -1652.87 -1823.39 -1915.56
Other Equity, Total -36.202 -15.552 -28.551 -27.475 3.984 0.534
Total Liabilities & Shareholders’ Equity 949.068 846.851 716.177 455.763 314.587 359.856
Total Common Shares Outstanding 118.689 122.087 160.02 163.275 187.663 206.74
Unrealized Gain (Loss) -0.002 -0.061 0.007 0.013 -0.331
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 144.118 156.685 153.092 156.628 154.937
Cash and Short Term Investments 105.686 115.106 114.412 115.16 112.142
Cash & Equivalents 27.355 36.412 41.728 42.92 40.321
Short Term Investments 78.331 78.694 72.684 72.24 71.821
Total Receivables, Net 21.357 26.671 21.083 21.471 24.866
Accounts Receivable - Trade, Net 20.802 26.038 20.235 20.905 24.323
Total Inventory 10.637 11.413 9.936 13.261 12.73
Prepaid Expenses 6.43 3.484 7.661 6.736 5.199
Other Current Assets, Total 0.008 0.011 0 0
Total Assets 406.984 402.573 376.899 359.856 335.568
Property/Plant/Equipment, Total - Net 42.355 45.072 44.522 45.215 44.546
Property/Plant/Equipment, Total - Gross 78.744 82.939 83.141 84.437 85.021
Accumulated Depreciation, Total -36.389 -37.867 -38.619 -39.222 -40.475
Goodwill, Net 54.238 54.273 54.206 54.148 53.613
Intangibles, Net 61.23 59.942 56.914 54.115 51.427
Long Term Investments 103.61 85.269 66.926 48.562 29.914
Other Long Term Assets, Total 1.433 1.332 1.239 1.188 1.131
Total Current Liabilities 25.243 28.869 28.989 34.645 25.601
Accounts Payable 4.295 4.937 3.624 5.405 4.415
Accrued Expenses 16.52 20.176 21.294 24.369 18.136
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.359 0.356 0.355 0.402 0.355
Other Current Liabilities, Total 4.069 3.4 3.716 4.469 2.695
Total Liabilities 232.189 243.377 245.652 252.508 261.732
Total Long Term Debt 174.158 176.922 179.817 182.749 201.112
Long Term Debt 174.158 176.922 179.817 182.749 201.112
Deferred Income Tax 2.722 2.692 2.574 2.539 2.438
Other Liabilities, Total 30.066 34.894 34.272 32.575 32.581
Total Equity 174.795 159.196 131.247 107.348 73.836
Common Stock 0 0 0 0 0
Additional Paid-In Capital 2013.76 2017.41 2020.25 2022.7 1991.67
Retained Earnings (Accumulated Deficit) -1840.71 -1860.76 -1890.52 -1915.56 -1916.14
Unrealized Gain (Loss) -0.035 -0.072 -0.03 -0.331 -1.133
Other Equity, Total 1.781 2.613 1.545 0.534 -0.566
Total Liabilities & Shareholders’ Equity 406.984 402.573 376.899 359.856 335.568
Total Common Shares Outstanding 206.414 206.581 206.738 206.74 207.693
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -190.274 -126.82 -514.706 -323.916 -170.521 -92.166
Cash From Operating Activities -48.988 -103.72 -124.24 -135.927 -77.021 -55.771
Cash From Operating Activities 24.572 31.145 33.112 24.896 17.516 13.761
Deferred Taxes -3.467 -2.528 -21.278 -3.674 -0.156 -0.167
Non-Cash Items 130.933 68.643 398.617 164.338 96.791 23.605
Cash Taxes Paid 0.01 0.566 0.216 0.05 0.048 0.036
Cash Interest Paid 0.964 0.617 3.868 3.751 7.202 7.155
Changes in Working Capital -10.752 -74.16 -19.985 2.429 -20.651 -0.804
Cash From Investing Activities -28.392 104.332 -151.213 86.851 27.779 -74.54
Capital Expenditures -38.873 -60.885 -41.587 -37.883 -7.527 -7.247
Other Investing Cash Flow Items, Total 10.481 165.217 -109.626 124.734 35.306 -67.293
Cash From Financing Activities 12.065 4.284 309.795 8.138 32.705 121.187
Financing Cash Flow Items -6.705 -9.601 0 0
Issuance (Retirement) of Stock, Net 19.165 14.666 90.326 6.924 35.117 121.653
Issuance (Retirement) of Debt, Net -0.395 -0.781 219.469 1.214 -2.412 -0.466
Foreign Exchange Effects -0.873 1.055 0.295 -0.81 0.353 0.217
Net Change in Cash -66.188 5.951 34.637 -41.748 -16.184 -8.907
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -17.318 -37.368 -67.132 -92.166 -19.251
Cash From Operating Activities -16.384 -24.16 -41.182 -55.771 -18.783
Cash From Operating Activities 3.523 7.043 10.442 13.761 3.292
Deferred Taxes -0.056 -0.119 -0.18 -0.167 -0.058
Non-Cash Items 4.021 12.038 18.827 23.605 5.629
Cash Taxes Paid 0.004 0.004 0.004 0.036 0
Cash Interest Paid 3.539 3.578 7.116 7.155 3.535
Changes in Working Capital -6.554 -5.754 -3.139 -0.804 -8.395
Cash From Investing Activities -129.102 -112.482 -90.469 -74.54 16.568
Capital Expenditures -1.014 -2.208 -4.474 -7.247 -1.579
Other Investing Cash Flow Items, Total -128.088 -110.274 -85.995 -67.293 18.147
Cash From Financing Activities 121.04 121.063 121.297 121.187 -0.163
Issuance (Retirement) of Stock, Net 121.156 121.297 121.648 121.653 0.001
Issuance (Retirement) of Debt, Net -0.116 -0.234 -0.351 -0.466 -0.164
Foreign Exchange Effects -0.011 0.184 0.264 0.217 -0.23
Net Change in Cash -24.457 -15.395 -10.09 -8.907 -2.608

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Precigen, Inc. Company profile

About Precigen Inc

Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The Company also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. It also has a robust pipeline of preclinical programs.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Precigen Inc revenues increased 1% to $103.9M. Net loss before extraordinary items decreased 7% to $96.8M. Revenues reflect Tranns Ova segment increase of 26% to $89.6M. Lower net loss reflects General and administrative - Balancing decrease of 15% to $63.2M (expense), Stock-based Compensation in SGA decrease of 38% to $11M (expense).

Equity composition

Common Stock, no Par, 08/13, 185M auth., 95,210,329 issd., Insider Owns approx.89.50%.

Industry: Pharmaceuticals (NEC)

20374 Seneca Meadows Parkway
GERMANTOWN
MARYLAND 20876
US

Income statement

People Also Watch

Ripple to US Dollar

0.34 Price
-10.310% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 21:00 (UTC)
Spread 0.00600

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading